Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Kanecia Obie Zimmerman
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05965726CT.gov RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms | — | Completed | — | — | — |
NCT05576662CT.gov Paxlovid for Treatment of Long Covid | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Long COVID-19
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| NORVIR (this asset) | Kanecia Obie Zimmerman | P2 | B · 62 |
| Immulina Tm | University of Mississippi Medical Center | P3 | BB |
| Ivabradine | Kanecia Obie Zimmerman | P2 | B |
| Sirolimus | Icahn School of Medicine at Mount Sinai | P3 | B |
| Solriamfetol | Duke University | P2 | B |
| Paxlovid | Kanecia Obie Zimmerman | P2 | B |
| Melatonin | Duke University | P2 | B |
| Metformin | Janneke van de Wijgert | P3 | B |
| Colchicinum | Janneke van de Wijgert | P3 | B |
+23 more in the Long COVID-19 cohort
Other indications for NORVIR
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Hepatitis C Virus Infection | — | P3 | BBB · 76 |
| Hepatitis C Virus Infection | — | P3 | BBB · 76 |
| HIV Infectious Disease | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. NORVIR in Long COVID-19. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/norvir-long-covid-19
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →